Gene Therapy via Trans-Splicing for LMNA-Related Congenital Muscular Dystrophy - Sorbonne Université
Journal Articles Molecular Therapy - Nucleic Acids Year : 2018

Gene Therapy via Trans-Splicing for LMNA-Related Congenital Muscular Dystrophy

Abstract

We assessed the potential of Lmna-mRNA repair by spliceosome-mediated RNA trans-splicing as a therapeutic approach for LMNA-related congenital muscular dystrophy. This gene therapy strategy leads to reduction of mutated transcript expression for the benefit of corresponding wild-type (WT) transcripts. We developed 5 0-RNA pretrans-splicing molecules containing the first five exons of Lmna and targeting intron 5 of Lmna pre-mRNA. Among nine pre-trans-splicing molecules, differing in the targeted sequence in intron 5 and tested in C2C12 myoblasts, three induced trans-splicing events on endogenous Lmna mRNA and confirmed at protein level. Further analyses performed in primary myotubes derived from an LMNA-related congenital muscular dystrophy (L-CMD) mouse model led to a partial rescue of the mutant phenotype. Finally, we tested this approach in vivo using adeno-associated virus (AAV) delivery in newborn mice and showed that trans-splicing events occurred in WT mice 50 days after AAV delivery, although at a low rate. Altogether, while these results provide the first evidence for reprogramming LMNA mRNA in vitro, strategies to improve the rate of trans-splicing events still need to be developed for efficient application of this therapeutic approach in vivo.
Fichier principal
Vignette du fichier
mmc2(1).pdf (4.1 Mo) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-03269960 , version 1 (24-06-2021)

Identifiers

Cite

Feriel Azibani, Astrid Brull, Ludovic Arandel, Maud Beuvin, Isabelle Nelson, et al.. Gene Therapy via Trans-Splicing for LMNA-Related Congenital Muscular Dystrophy. Molecular Therapy - Nucleic Acids, 2018, 10, pp.376 - 386. ⟨10.1016/j.omtn.2017.12.012⟩. ⟨hal-03269960⟩
51 View
75 Download

Altmetric

Share

More